Long noncoding RNAs: role and contribution in pancreatic cancer

Devi, Ramya; Karthik, Dharshene; Mahendran, TharunSelvam; Jaganathan, M K; Hemdev, Sanjana Prakash

doi:10.1080/21541264.2021.1922071

Cited by 12 publications

(17 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This phenomenon leads to the deregulation of miRNA function with several effects on the genome. Modulation of PVT1 that takes part in pancreatic carcinogenesis and chemoresistance to gemcitabine, is also considered a potent druggable target, while it is proven that the knockdown of PVT1could suppress the autophagy mechanism and limit the chemoresistance to gemcitabine by miR-143/HIF-1α/VMP1 axis [ 114 , 115 , 116 , 117 , 118 , 119 , 120 ]. Another example of miRNA-related autophagy inhibition that suppresses PDAC grow this mediated by miR-7 and miR-372 [ 121 , 122 ].…”

Section: The Interplay Of Autophagy and Mirnas In Pdacmentioning

confidence: 99%

The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches

Koustas

Trifylli²,

Sarantis

et al. 2022

Genes

View full text Add to dashboard Cite

Pancreatic cancer constitutes the fourth most frequent cause of death due to malignancy in the US. Despite the new therapeutic modalities, the management of pancreatic ductal adenocarcinoma (PDAC) is considered a difficult task for clinicians due to the fact that is usually diagnosed in already advanced stages and it is relatively resistant to the current chemotherapeutic agents. The molecular background analysis of pancreatic malignant tumors, which includes various epigenetic and genetic alterations, opens new horizons for the development of novel diagnostic and therapeutic strategies. The interplay between miRNAs, autophagy pathway, and pancreatic carcinogenesis is in the spotlight of the current research. There is strong evidence that miRNAs take part in carcinogenesis either as tumor inhibitors that combat the oncogene expression or as promoters (oncomiRs) by acting as oncogenes by interfering with various cell functions such as proliferation, programmed cell death, and metabolic and signaling pathways. Deregulation of the expression levels of various miRNAs is closely associated with tumor growth, progression, and dissemination, as well as low sensitivity to chemotherapeutic agents. Similarly, autophagy despite constituting a pivotal homeostatic mechanism for cell survival has a binary role in PDAC, either as an inhibitor or promoter of carcinogenesis. The emerging role of miRNAs in autophagy gets a great deal of attention as it opens new opportunities for the development of novel therapeutic strategies for the management of this aggressive and chemoresistant malignancy. In this review, we will shed light on the interplay between miRNAs and the autophagy mechanism for pancreatic cancer development and progression.

show abstract

Section: The Interplay Of Autophagy and Mirnas In Pdacmentioning

confidence: 99%

The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches

Koustas

Trifylli²,

Sarantis

et al. 2022

Genes

View full text Add to dashboard Cite

show abstract

“…Early diagnosis [39] HOTAIR MALAT-1 Prognosis [40] LINC00460 Prognosis [41] PVT1 Monitoring treatment response [42] Circulating tumour cells Diagnosis [43] Prognosis [44] Vimentin (surface marker) Monitoring treatment response [45] Monitoring tumour recurrence [46] Metabolites Panel of acetylspermidine, diacetylspermine, indole-derivative and two lysophosphatidylcholines…”

Section: Snhg15mentioning

confidence: 99%

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Vellan

Jayapalan

Yoong

et al. 2022

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive malignancy with a poor prognosis is usually detected at the advanced stage of the disease. The only US Food and Drug Administration-approved biomarker that is available for PDAC, CA 19-9, is most useful in monitoring treatment response among PDAC patients rather than for early detection. Moreover, when CA 19-9 is solely used for diagnostic purposes, it has only a recorded sensitivity of 79% and specificity of 82% in symptomatic individuals. Therefore, there is an urgent need to identify reliable biomarkers for diagnosis (specifically for the early diagnosis), ascertain prognosis as well as to monitor treatment response and tumour recurrence of PDAC. In recent years, proteomic technologies are growing exponentially at an accelerated rate for a wide range of applications in cancer research. In this review, we discussed the current status of biomarker research for PDAC using various proteomic technologies. This review will explore the potential perspective for understanding and identifying the unique alterations in protein expressions that could prove beneficial in discovering new robust biomarkers to detect PDAC at an early stage, ascertain prognosis of patients with the disease in addition to monitoring treatment response and tumour recurrence of patients.

show abstract

“…LncRNA LINC01111 is a novel long intergenic ncRNA and located at chromosome 8q21.13 ( 80 , 81 ). Pan et al.…”

Section: Linc01111/mir-3924/dusp1mentioning

confidence: 99%

Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer

et al. 2021

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a highly malignant disease characterized by insidious onset, rapid progress, and poor therapeutic effects. The molecular mechanisms associated with PC initiation and progression are largely insufficient, hampering the exploitation of novel diagnostic biomarkers and development of efficient therapeutic strategies. Emerging evidence recently reveals that noncoding RNAs (ncRNAs), including long ncRNAs (lncRNAs) and microRNAs (miRNAs), extensively participate in PC pathogenesis. Specifically, lncRNAs can function as competing endogenous RNAs (ceRNAs), competitively sequestering miRNAs, therefore modulating the expression levels of their downstream target genes. Such complex lncRNA/miRNA/mRNA networks, namely, ceRNA networks, play crucial roles in the biological processes of PC by regulating cell growth and survival, epithelial–mesenchymal transition and metastasis, cancer stem cell maintenance, metabolism, autophagy, chemoresistance, and angiogenesis. In this review, the emerging knowledge on the lncRNA-associated ceRNA networks involved in PC initiation and progression will be summarized, and the potentials of the competitive crosstalk as diagnostic, prognostic, and therapeutic targets will be comprehensively discussed.

show abstract

Long noncoding RNAs: role and contribution in pancreatic cancer

Cited by 12 publications

References 139 publications

The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches

The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer

Contact Info

Product

Resources

About